DUBLIN--(BUSINESS WIRE)--The "Global Alzheimers Diagnosis and Drugs Market - Growth, Trends And Forecast 2017 - 2022" report has been added to Research and Markets' offering.
The global Alzheimer's disease market is estimated to be approximately $10 billion for the year 2015.
Due to drug patent expirations in 2017 and many generics entering the market, it is expected to see a declination in the market growth by the year 2017. The market is anticipated to grow driven by the disease-modifying drugs, and the vast last-stage pipeline drugs. The prevalence of Alzheimer's in the USA is almost 5 million and due to the increasing aging populations it is expected to grow further, also at the global level.
The major concern in the Alzheimer's disease is detection of the condition in the patient. Blood biomarkers will help to detect the early onset of alzheimers which would help in the treatment of the disease. Based on this, investment in the production of biomarkers is considered to be an advantage for the companies. Most of the pipeline drugs for Alzheimers' fail in the late stage and there are only few drugs for this indication. Investing in the drug pipeline for Alzheimer's is also beneficiary. There is a lack of surrogate markers for drug discovery and development. Development of surrogate markers will have definite effectiveness for the treatment of neurologic or psychiatric disease.
The market segmented by therapeutics which includes cholinesterase inhibitors, biomarkers and NMDA receptor anatagonists and by diagnostics which include brain imaging and blood tests. The major drugs in the Alzheimers market are Nameda, Aricept and Exelon and the expected decline of the market is due to patent expirations of Namenda and Aricept.
The major companies for therapeutics market are Roche, Novartis, Eisai and for diagnostics are GE Healthcare and Eli Lilly.
AstraZeneca's current research on a new drug for Alzheimer's disease treatment, if succeeded, is estimate to be a market potential of $5 billion.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Market Overview
4. Market Segmentation
5. Competitive Landscape
6. Company Profiles
- Roche
- Genentech
- Novartis
- Merck
- Pfizer
- Eisai
- Bayer Pharmaceuticals
- Pfizer
- Daichi Sankyo
- Biogen
- Eli Lilly
- Amarantus Bioscience Holdings
- GE Healthcare
- Diagenic
- Navidea
For more information about this report visit https://www.researchandmarkets.com/research/29n87l/global_alzheimers
